MedRxiv: The new marker detects the severity of COVID19.

, June 21, 2020 /PRNewswire/ --- Common symptoms in patients with BIOON/--- coVID19 include cough, fever, fatigue and breathing difficultiesAlthough most patients infected with the virus have no or only mild symptoms, some develop severe pneumonia, acute respiratory distress syndrome (ARDS), multiple organ failure and deathWhile it is not clear why some people are protected from severe COVID-19, others have a higher risk of deathIn a recent study, scientists at the University of Louisville identified biomarkers that could predict the critical risk of SARS-CoV-2 infection in patientsestimates that 20% of PATIENTS with COVID-19 develop serious illnessesSome of these patients may have immune cells rapidly cluster ingress to the lungs to fight infectionBut at the same time they can cause inflammation and clotting dysfunction, leading to pulmonary embolism, heart disease, stroke and deep vein thrombosis (DVT), which can be fatal(photo source:to understand the severe risk associated with COVID19, the authors assessed the levels of multiple immune cells in blood samples in patients with COVID-19 and compared them with blood samples from healthy people, according to an article published in the preprinted journal MedRxiv, the team found that in some severe cases, a particular type of immune cell (low-density inflammatory neutrophils) had significantly higher levels, indicating an increased risk of death, and a significant increase in the risk of death within a few daysneutrophils are white blood cells that help repair damaged tissue and eliminate infectionsDuring infection, the blood level of neutrophils increasesDuring infection, neutrophils are responsible for removing pathogensHowever, when its level continues to rise, it can have a negative impactevidence suggests that patients with severe COVID-19 may develop cytokine storm syndrome, which triggers a large number of cytokine production, which attracts too many immune cells, such as neutrophil aggregationAs a result, immune cells penetrate into lung tissue and cause damagein worse cases, cytokine storms can cause excessive leakage of blood vessels, a sharp drop in blood pressure, blood clotting and hypoxiaThis eventually leads to the failure of the multi-organ systemthe team believes the discovery of new biomarkers could help clinicians monitor the progression of disease in hospitalized patientsIn addition, the development of a simple test to predict the severity of the disease can be used to help mitigate the effects of the disease through appropriate surveillance and treatmentresearchers believe that the low-density inflammatory neutrophil population drives the occurrence of COVID-19-related coagulation disease and can therefore be used as a clinical marker for predicting disease progressionit is important to identify patients who may be in a cell crisisThe researchers stress that early implementation of appropriate treatment can be effective in reducing the mortality rate of PATIENTs with COVID-19The team is currently working with other scientists to test potential drugs and therapies(Bio Valley Bioon.com)Source:Discovery of biomarkers that can covid-19 severity
original origin:Morrissey, S., Geller, A., Hu, X., Yan, Jet al(2020)Yn Ywy Low-density y ei lyny Neutrophils Correlates with Hypercoagulable State and Disease Severity in COVID-19 Patients.
Med Rxiv